Featured
Single-Dose CRISPR Base Editing Therapy Achieves Permanent 90% Triglyceride Reduction in Landmark Cardiovascular Trial
Landmark Phase 1b/2 trial data reveals that a single-dose in-vivo CRISPR base editing therapy targeting ANGPTL3 achieves a permanent 90% reduction in ...
Read Full Story →